Special Issue

Vaccines against Flaviviruses and Alphaviruses: Recent Advances and Future Challenges

Message from the Guest Editors

The mosquito-borne viruses such as Dengue (DENV), Zika (ZIKV) and Chikungunya (CHIKV) viruses have emerged in recent decades affecting millions of people worldwide. These flaviviruses and alphaviruses can be classified into a broader category of arboviruses, and they cause significant disease burdens and public health concerns. Vaccine development against arboviruses has experienced swift progress after the sudden (re)emergence of cases of DENV, CHIKV and ZIKV in the last two decades. Despite the fact that there are no licensed vaccines against ZIKV and CHIKV, the wide range of vaccine platforms including both classic and new approaches such as inactivated and attenuated, proteins, virus-like particles (VLPs), viral vectors, DNA and mRNA are currently being tested in pre-clinical studies and in clinical trials which could lead to the future licensing of vaccines. This Special Issue will feature vaccines against flaviviruses and alphaviruses of medical importance in humans with a particular focus on the design, development and validation of new vaccine candidates and the animal model.

Guest Editors

Dr. Young Chan Kim

1. Centre for Human Genetics, Division of Structural Biology, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
2. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK

Dr. Arturo Reyes-Sandoval

1. The Jenner Institute, ORCRB, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK
2. Instituto Politécnico Nacional, IPN, Av. Luis Enrique Erro s/n, Unidad Adolfo López Mateos, Mexico City, Mexico

Deadline for manuscript submissions

closed (30 June 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/134093

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).